HomeInsightsStock Comparison

Eris Lifesciences Ltd vs Morepen Laboratories Ltd Stock Comparison

Eris Lifesciences Ltd vs Morepen Laboratories Ltd Stock Comparison

Last Updated on: Jul 16, 2025

Key Highlights

  • The Latest Trading Price of ERIS Lifesciences Ltd is ₹ 1782 as of 16 Jul 14:55.
  • The P/E Ratio of ERIS Lifesciences Ltd changed from 16.9 on March 2020 to 54.8 on March 2025 . This represents a CAGR of 21.66% over 6 yearsThe P/E Ratio of Morepen Laboratories Ltd changed from 12.7 on March 2020 to 0 on March 2025 . This represents a CAGR of -100.00% over 6 years.
  • The Market Cap of ERIS Lifesciences Ltd changed from ₹ 5003 crore on March 2020 to ₹ 19287 crore on March 2025 . This represents a CAGR of 25.22% over 6 yearsThe Market Cap of Morepen Laboratories Ltd changed from ₹ 429.13 crore on March 2020 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 6 years.
  • The revenue of ERIS Lifesciences Ltd for the Mar '25 is ₹ 713.31 crore as compare to the Dec '24 revenue of ₹ 731.67 crore. This represent the decline of -2.51% The revenue of Morepen Laboratories Ltd for the Mar '25 is ₹ 470.46 crore as compare to the Dec '24 revenue of ₹ 458.12 crore. This represent the growth of 2.69%.
  • The ebitda of ERIS Lifesciences Ltd for the Mar '25 is ₹ 260.4 crore as compare to the Dec '24 ebitda of ₹ 254.53 crore. This represent the growth of 2.31% The ebitda of Morepen Laboratories Ltd for the Mar '25 is ₹ 46.85 crore as compare to the Dec '24 ebitda of ₹ 41.48 crore. This represent the growth of 12.95%.
  • The net profit of ERIS Lifesciences Ltd changed from ₹ 93.65 crore to ₹ 102.35 crore over 8 quarters. This represents a CAGR of 4.54% The net profit of Morepen Laboratories Ltd changed from ₹ 14.63 crore to ₹ 20.31 crore over 8 quarters. This represents a CAGR of 17.82% .
  • The Dividend Payout of ERIS Lifesciences Ltd changed from 13.76 % on March 2020 to 129.35 % on March 2025 . This represents a CAGR of 45.28% over 6 yearsThe Dividend Payout of Morepen Laboratories Ltd changed from 0 % on March 2020 to 0 % on March 2025 . This represents a CAGR of 0.0% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About ERIS Lifesciences Ltd

  • Eris Lifesciences Limited was incorporated on January 25, 2007.
  • Subsequently, the name of the company was changed to 'Eris Lifesciences Private Limited' on February 9, 2007.
  • Further, the Company was converted into a Public Limited cCompany and the name was changed to 'Eris Lifesciences Limited' on February 2, 2017.
  • The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products.
  • It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors. The company develops, manufactures and commercializes branded pharmaceutical products in selected therapeutic areas within chronic and acute categories of the Indian Pharmaceutical Market (IPM), such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infective.

About Morepen Laboratories Ltd

  • Morepen Laboratories Limited is an India-based pharmaceutical company.
  • Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
  • The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
  • It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
  • The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.

ERIS Lifesciences Ltd News Hub

News

ERIS Lifesciences to conduct AGM

ERIS Lifesciences announced that the 19th Annual General Meeting(AGM) of the company will ...

Read more

01 Jul 2025 14:20

News

Eris Lifesciences gains after Q4 PAT climbs 32% YoY to Rs 94 cr

Profit before tax (PBT) climbed 67.9% YoY to Rs 128.87 crore in Q4 FY25. During the quarte...

Read more

20 May 2025 13:08

News

ERIS Lifesciences to hold board meeting

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 19 May 2...

Read more

14 May 2025 16:22

News

Eris Lifesciences allots 33,287 equity shares under ESOP

Eris Lifesciences has allotted 33,287 equity shares under ESOP on 06 March 2025. The paid-...

Read more

06 Mar 2025 13:17

News

Eris Lifesciences avails credit facility of Rs 1,000 cr

Eris Lifesciences has availed credit facilities amounting to Rs 1000 crore from Kotak Mahi...

Read more

21 Feb 2025 09:22

News

Board of ERIS Lifesciences recommends Interim Dividend

ERIS Lifesciences announced that the Board of Directors of the Company at its meeting held...

Read more

07 Feb 2025 16:36

Morepen Laboratories Ltd News Hub

News

Morpen Labs incorporates subsidiary in Dubai

The newly formed wholly owned subsidiary namely Morepen Labs ' FZCO, will trade in pharmac...

Read more

19 Jun 2025 08:44

News

Board of Morepen Laboratories approves availing of working capital loan of Rs 50 cr

The Board of Morepen Laboratories at its meeting held on 23 May 2025 has approved inter-al...

Read more

23 May 2025 10:25

News

Board of Morepen Laboratories notes incorporation of step-down subsidiary in Dubai

The Board of Morepen Laboratories at its meeting held on 12 May 2025 has noted the decisio...

Read more

12 May 2025 18:29

News

Board of Morepen Laboratories recommends Final Dividend

Morepen Laboratories announced that the Board of Directors of the Company at its meeting h...

Read more

12 May 2025 16:11

News

Morepen Laboratories to announce Quarterly Result

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 12 Ma...

Read more

06 May 2025 11:55

News

Morepen receives CDSCO nod to conduct BE studies for Resmetirom

Morepen Laboratories has got clearance from Subject Expert Committee (SEC) of Central Drug...

Read more

29 Apr 2025 09:07

SWOT Analysis Of ERIS Lifesciences Ltd

Strength

4

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Morepen Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for ERIS Lifesciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Morepen Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of ERIS Lifesciences Ltd and Morepen Laboratories Ltd

Which company has a larger market capitalization, ERIS Lifesciences Ltd or Morepen Laboratories Ltd?

Market cap of ERIS Lifesciences Ltd is 23,886 Cr while Market cap of Morepen Laboratories Ltd is 3,452 Cr

What are the key factors driving the stock performance of ERIS Lifesciences Ltd and Morepen Laboratories Ltd?

The stock performance of ERIS Lifesciences Ltd and Morepen Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for ERIS Lifesciences Ltd and Morepen Laboratories Ltd?

As of July 16, 2025, the ERIS Lifesciences Ltd stock price is INR ₹1753.85. On the other hand, Morepen Laboratories Ltd stock price is INR ₹63.01.

How do dividend payouts of ERIS Lifesciences Ltd and Morepen Laboratories Ltd compare?

To compare the dividend payouts of ERIS Lifesciences Ltd and Morepen Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions